DNA SEQ 2, INC. — SEC Form D Filing

DNA SEQ 2, INC. filed an SEC Form D on March 11, 2026, reporting $1.18M raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
March 11, 2026
Amount reported
$1.18M
Round stage
Seed
Industry
Pharmaceuticals
Website
https://www.dnaseq.io/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Cancer treatments often fail due to drug resistance, rendering existing therapies ineffective over time.

Solution

DNA SEQ uses AI and machine learning to identify novel binding sites for drug candidates, allowing for the design of new drugs that can overcome resistance.

Why now

Advancements in AI and machine learning have created new opportunities for drug discovery, particularly in addressing challenges like drug resistance in cancer treatments.

Verdict

Investors said yes to DNA SEQ 2, INC. because the promise of overcoming drug resistance positioned the company at the cutting edge of pharmaceutical innovation, not simply as another AI platform. They were implicitly betting on the scalability of AI-driven methodologies and the potential to capture substantial market share in a desperate healthcare ecosystem. However, the upside is limited due to the high barriers of regulatory approval and the complexity of validating AI outputs, which could hinder longevity and wide adoption in a crowded field.

Source: SEC EDGAR Form D filing